Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 - New Study Released

From: Fast Market Research, Inc.
Published: Wed Mar 25 2015


Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA. Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).

Full Report Details at
- http://www.fastmr.com/prod/966196_eluxadoline_irritable_bowel_syndrome_forecast_and.aspx?afid=301

Scope

* Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Eluxadoline including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Eluxadoline for the top 7 countries from 2013 to 2023.
* Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return.
* Stay ahead of the competition by understanding the changing competitive landscape for IBS.
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
* Make more informed business decisions from insightful and in-depth analysis of Eluxadoline performance.
* Obtain sales forecast for Eluxadoline from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023
- Plecanatide (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »